ArticleNature communications2018
A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Surgical strategies and long-term survival for third ventricle chordoid gliomas: a systematic review and clinical algorithm.Neurosurgical review · 2026Pooled it
- Management of Anterior Third Ventricular Tumors: A Comprehensive Review and Clinical Experience.Advances and technical standards in neurosurgery · 2026Review
- Role of PRKCZ non-synonymous genetic variants in breast cancer development.Cancer cell international · 2025Article
- The chordoid gliomaScience signaling · 2025Article
- Identifying therapeutic targets for erectile dysfunction in the European population using genome-wide Mendelian randomization.Sexual medicine · 2025Article
- Establishment of High-Throughput Screening Assay using 384-Well Plate for Identification of Potent Antioxidants from Malaysian Local Plants Repository and Phytochemical Profile ofTropical life sciences research · 2025Article
- GETgene-AI: a framework for prioritizing actionable cancer drug targets.Frontiers in systems biology · 2025Article
- PKCα Activation via the Thyroid Hormone Membrane Receptor Is Key to Thyroid Cancer Growth.International journal of molecular sciences · 2024Article
- Metabolism: an important player in glioma survival and development.Discover oncology · 2024Review
- Glioma.Nature reviews. Disease primers · 2024Review
- Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?Frontiers in molecular neuroscience · 2024Review
- Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response.Biology · 2023Review
- Major Features of the 2021 WHO Classification of CNS Tumors.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity.Science signaling · 2022Review
- Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas.Acta neuropathologica communications · 2022Article
- ScaffComb: A Phenotype-Based Framework for Drug Combination Virtual Screening in Large-Scale Chemical Datasets.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma.Bioengineered · 2021Article
- Molecular Mechanisms of Antiproliferative and Apoptosis Activity by 1,5-Bis(4-Hydroxy-3-Methoxyphenyl)1,4-Pentadiene-3-one (MS13) on Human Non-Small Cell Lung Cancer Cells.International journal of molecular sciences · 2021Article
- EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling.Molecular cancer · 2021Article
- Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma.Brain pathology (Zurich, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 9 institutions in 4 countries.
Shai RosenbergInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.ORCID http://orcid.org/0000-0001-6309-6933
Iva SimeonovaInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Franck BielleInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Maite VerreaultInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Bertille BanceInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Isabelle Le RouxInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Mailys DaniauInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Arun NadaradjaneInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Vincent GleizeInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Sophie ParisInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Yannick MarieInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Marine GiryInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Marc PolivkaDepartment of Pathology, AP-HP, Hôpital Lariboisière, F-75010, Paris, France.
Dominique Figarella-BrangerPathology and Neuropathology Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), CHU Timone, 13005, Marseille, France.
Marie-Hélène Aubriot-LortonDepartment of Pathology and CRB Ferdinand Cabanne, CHU Dijon Bourgogne, 21000, Dijon, France.
Chiara VillaDepartment of Pathological Cytology and Anatomy, Foch Hospital, Suresnes, F-92151, Paris, France.
Alexandre VasiljevicCentre de Biologie et Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500, Bron, France.
Emmanuèle Lechapt-ZalcmanDepartment of Pathology, CHU de Caen, Caen, France Normandie Univ, UNICAEN, CEA, CNRS, ISTCT/LDM-TEP Group, 14000, Caen, France.
Michel KalamaridesInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Ariane SharifINSERM U1172, "Development and Plasticity of the Neuroendocrine Brain", F-59045, Lille, France.
Karima MokhtariInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Stefano Maria PagnottaDipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, 82100, Benevento, Italy.
Antonio IavaroneInstitute for Cancer Genetics, Columbia University Medical Center, New York City, NY, 10032, USA.
Anna LasorellaInstitute for Cancer Genetics, Columbia University Medical Center, New York City, NY, 10032, USA.
Emmanuelle HuillardInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France.
Marc SansonInserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, ICM, F-75013, Paris, France. marc.sanson@aphp.fr.
Centre National de la Recherche Scientifique · FRColumbia University Irving Medical Center · USAssistance Publique Hôpitaux de Marseille · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Foch · FRHospices Civils de Lyon · FRInserm · FRUniversité de Bourgogne · FRUniversity of Sannio · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoid glioma (ChG) is a characteristic, slow growing, and well-circumscribed diencephalic tumor, whose mutational landscape is unknown. Here we report the analysis of 16 ChG by whole-exome and RNA-sequencing. We found that 15 ChG harbor the same PRKCA
Indexed as
AdultAgedCell ProliferationCells, CulturedCerebral Ventricle NeoplasmsFemaleGliomaHumansMaleMiddle AgedPoint MutationProtein Kinase C-alphaPRKCA protein, humanProtein Kinase C-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.